{"product_id":"nuxipim-500mg-1g-injection-cefepime-pharma-services-group","title":"NUXIPIM 500mg \u0026 1g Injection (Cefepime) | Pharma Services Group","description":"\u003ch1 class=\"isSelectedEnd\"\u003e\u003cstrong\u003eNUXIPIM Injection contains Cefepime, \u003c\/strong\u003e\u003c\/h1\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eA fourth-generation cephalosporin antibiotic available in 500mg and 1g strengths for intravenous (IV) or intramuscular (IM) administration.\u003c\/strong\u003e The attached packaging identifies NUXIPIM as \u003cstrong\u003eCefepime Injection\u003c\/strong\u003e and shows both \u003cstrong\u003e500mg and 1g\u003c\/strong\u003e presentations. Bosch Pharmaceuticals lists NUXIPIM 500mg and NUXIPIM 1000mg as injectable Cefepime products and specifies Cefepime hydrochloride with sterile arginine \u003cstrong\u003eCefepime injection\u003c\/strong\u003e is a broad-spectrum, bactericidal antibiotic used for the treatment of susceptible bacterial infections, including certain respiratory tract, urinary tract, skin and soft-tissue infections and other serious infections as determined by a healthcare professional. The choice between \u003cstrong\u003eNUXIPIM 500mg and NUXIPIM 1g\u003c\/strong\u003e depends on factors such as the type and severity of infection, age, body weight and kidney function. Cefepime is a prescription antibiotic and should be administered only according to a qualified healthcare professional's instructions.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eAvailable Strengths\u003c\/h2\u003e\r\\n\u003ctable\u003e\r\\n\u003ctbody\u003e\r\\n\u003ctr\u003e\r\\n\u003cth\u003eProduct Variant\u003c\/th\u003e\r\\n\u003cth\u003eStrength\u003c\/th\u003e\r\\n\u003cth\u003eRoute\u003c\/th\u003e\r\\n\u003cth\u003ePack Presentation\u003c\/th\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eNUXIPIM 500mg Injection\u003c\/td\u003e\r\\n\u003ctd\u003eCefepime 500mg\u003c\/td\u003e\r\\n\u003ctd\u003eIV \/ IM\u003c\/td\u003e\r\\n\u003ctd\u003e1 vial + 5mL sterile water for injection\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eNUXIPIM 1g Injection\u003c\/td\u003e\r\\n\u003ctd\u003eCefepime 1000mg\u003c\/td\u003e\r\\n\u003ctd\u003eIV \/ IM\u003c\/td\u003e\r\\n\u003ctd\u003e1 vial + 10mL sterile water for injection\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003c\/tbody\u003e\r\\n\u003c\/table\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eThe manufacturer specifies separate solvent volumes for the 500mg and 1g presentations.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eKey Benefits\u003c\/h2\u003e\r\\n\u003cul data-spread=\"false\"\u003e\r\\n \t\u003cli\u003eContains \u003cstrong\u003eCefepime\u003c\/strong\u003e, a fourth-generation cephalosporin antibiotic.\u003c\/li\u003e\r\\n \t\u003cli\u003eAvailable in convenient \u003cstrong\u003e500mg and 1g injection strengths\u003c\/strong\u003e.\u003c\/li\u003e\r\\n \t\u003cli\u003eProvides broad-spectrum antibacterial activity against susceptible Gram-positive and Gram-negative bacteria.\u003c\/li\u003e\r\\n \t\u003cli\u003eCan be administered by \u003cstrong\u003eIV or IM route\u003c\/strong\u003e, depending on the clinical situation.\u003c\/li\u003e\r\\n \t\u003cli\u003eUsed in hospital and clinical settings for susceptible bacterial infections.\u003c\/li\u003e\r\\n \t\u003cli\u003eThe 1g presentation may be selected for infections requiring a higher prescribed dose.\u003c\/li\u003e\r\\n \t\u003cli\u003eManufactured by \u003cstrong\u003eBosch Pharmaceuticals (Pvt.) Ltd., Pakistan\u003c\/strong\u003e.\u003c\/li\u003e\r\\n\u003c\/ul\u003e\r\\n\u003ch2\u003eHow It Works\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eCefepime is a \u003cstrong\u003ebactericidal beta-lactam antibiotic\u003c\/strong\u003e. It works by interfering with bacterial cell-wall synthesis, ultimately causing susceptible bacteria to die. Cefepime has activity against a broad range of Gram-positive and Gram-negative organisms and is classified pharmacologically as a \u003cstrong\u003efourth-generation cephalosporin\u003c\/strong\u003e.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eDirections for Use\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eNUXIPIM should be \u003cstrong\u003ereconstituted and administered by a qualified healthcare professional\u003c\/strong\u003e. It may be administered by intravenous injection, intravenous infusion or intramuscular injection according to the prescribed regimen and clinical requirements.\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eThe prescribed dose depends on the infection being treated, its severity, the patient's age and weight, and kidney function. Patients with renal impairment generally require dosage adjustment because cefepime is primarily eliminated through the kidneys.\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eFor the manufacturer's presentations, the stated reconstitution volumes include \u003cstrong\u003e5mL solvent for the 500mg IV presentation and 10mL for the 1g IV presentation\u003c\/strong\u003e. The product information also provides separate volumes for IM administration. Preparation should always follow the approved prescribing information and healthcare-facility procedures.\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eDo not self-administer NUXIPIM Injection.\u003c\/strong\u003e\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eUses \/ Therapeutic Applications\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eNUXIPIM (Cefepime) may be prescribed for susceptible bacterial infections, including:\u003c\/p\u003e\r\\n\r\\n\u003cul data-spread=\"false\"\u003e\r\\n \t\u003cli\u003eMild to moderate urinary tract infections.\u003c\/li\u003e\r\\n \t\u003cli\u003eOther susceptible mild to moderate bacterial infections.\u003c\/li\u003e\r\\n \t\u003cli\u003eSerious bacterial infections requiring parenteral antibiotic therapy.\u003c\/li\u003e\r\\n \t\u003cli\u003eCertain respiratory tract infections.\u003c\/li\u003e\r\\n \t\u003cli\u003eInfections caused by susceptible Gram-positive and Gram-negative organisms.\u003c\/li\u003e\r\\n \t\u003cli\u003eInfections involving organisms such as \u003cem\u003ePseudomonas aeruginosa\u003c\/em\u003e, when clinically appropriate and susceptible.\u003c\/li\u003e\r\\n\u003c\/ul\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eThe exact indication should be determined by the treating healthcare professional based on the patient's condition and microbiological information when available.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003ePrecautions\u003c\/h2\u003e\r\\n\u003cul data-spread=\"false\"\u003e\r\\n \t\u003cli\u003eNUXIPIM is a \u003cstrong\u003eprescription antibiotic\u003c\/strong\u003e and should only be used under medical supervision.\u003c\/li\u003e\r\\n \t\u003cli\u003eDo not use in patients with a known immediate hypersensitivity to \u003cstrong\u003eCefepime, cephalosporins or other beta-lactam antibiotics\u003c\/strong\u003e.\u003c\/li\u003e\r\\n \t\u003cli\u003eTell your doctor about previous serious allergies to penicillins, cephalosporins or other antibiotics.\u003c\/li\u003e\r\\n \t\u003cli\u003ePatients with \u003cstrong\u003ekidney impairment\u003c\/strong\u003e may require dosage adjustment.\u003c\/li\u003e\r\\n \t\u003cli\u003eCefepime may cause neurological adverse effects, particularly when inappropriate doses are used in patients with renal impairment.\u003c\/li\u003e\r\\n \t\u003cli\u003eInform your doctor about all medicines you are taking before receiving Cefepime.\u003c\/li\u003e\r\\n \t\u003cli\u003eAntibiotics should not be used to treat viral infections such as ordinary colds or influenza.\u003c\/li\u003e\r\\n \t\u003cli\u003eComplete the prescribed treatment course unless your healthcare professional specifically advises otherwise.\u003c\/li\u003e\r\\n \t\u003cli\u003eDuring pregnancy or breastfeeding, use only when considered necessary by a healthcare professional.\u003c\/li\u003e\r\\n\u003c\/ul\u003e\r\\n\u003ch2\u003ePossible Side Effects\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003ePossible adverse effects associated with Cefepime may include \u003cstrong\u003einjection-site reactions, diarrhea, nausea, vomiting, headache, rash and gastrointestinal discomfort\u003c\/strong\u003e. Less common but potentially serious reactions include severe allergic reactions and neurological effects such as confusion, hallucinations, encephalopathy, myoclonus or seizures, particularly in patients with renal impairment or excessive exposure.\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eSeek urgent medical attention if severe allergic symptoms, difficulty breathing, facial swelling, severe skin reactions, seizures or significant changes in consciousness occur.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eDrug Interactions\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eTell your healthcare professional about all medicines you are receiving. The manufacturer's prescribing information notes physical-chemical incompatibilities with certain injectable medicines, including \u003cstrong\u003emetronidazole, vancomycin, gentamicin, tobramycin, netilmicin and aminophylline\u003c\/strong\u003e, meaning they should not be mixed or administered through the same IV route without appropriate compatibility management.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eStorage Instructions\u003c\/h2\u003e\r\\n\u003cul data-spread=\"false\"\u003e\r\\n \t\u003cli\u003eStore the dry powder \u003cstrong\u003ebelow 25°C\u003c\/strong\u003e, according to the manufacturer's instructions.\u003c\/li\u003e\r\\n \t\u003cli\u003eProtect from heat, sunlight and moisture.\u003c\/li\u003e\r\\n \t\u003cli\u003eKeep the vial in its original packaging until required.\u003c\/li\u003e\r\\n \t\u003cli\u003eKeep out of reach of children.\u003c\/li\u003e\r\\n \t\u003cli\u003eReconstituted solutions should be handled according to the manufacturer's stability and healthcare-facility requirements.\u003c\/li\u003e\r\\n \t\u003cli\u003eInspect the prepared solution before administration and do not use if visible particles are present.\u003c\/li\u003e\r\\n \t\u003cli\u003eThe vial is intended for \u003cstrong\u003esingle use\u003c\/strong\u003e and remaining reconstituted solution should be discarded according to appropriate procedures.\u003c\/li\u003e\r\\n\u003c\/ul\u003e\r\\n\u003ch2\u003eManufacturer Information\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eBrand:\u003c\/strong\u003e NUXIPIM\r\\n\u003cstrong\u003eGeneric Name:\u003c\/strong\u003e Cefepime\r\\n\u003cstrong\u003eManufacturer:\u003c\/strong\u003e Bosch Pharmaceuticals (Pvt.) Ltd.\r\\n\u003cstrong\u003eCountry:\u003c\/strong\u003e Pakistan\r\\n\u003cstrong\u003eTherapeutic Segment:\u003c\/strong\u003e Antibiotic \/ Cephalosporin\r\\n\u003cstrong\u003ePharmacological Class:\u003c\/strong\u003e Fourth-Generation Cephalosporin\r\\n\u003cstrong\u003eAvailable Strengths:\u003c\/strong\u003e 500mg and 1g\r\\n\u003cstrong\u003eRoutes:\u003c\/strong\u003e IV \/ IM\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eBosch Pharmaceuticals' official product information confirms NUXIPIM as a Cefepime antibiotic and lists both \u003cstrong\u003e500mg and 1000mg injection\u003c\/strong\u003e presentations.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eProduct Specifications\u003c\/h2\u003e\r\\n\u003ctable\u003e\r\\n\u003ctbody\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eSpecification\u003c\/td\u003e\r\\n\u003ctd\u003eNUXIPIM 500mg\u003c\/td\u003e\r\\n\u003ctd\u003eNUXIPIM 1g\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eBrand Name\u003c\/td\u003e\r\\n\u003ctd\u003eNUXIPIM\u003c\/td\u003e\r\\n\u003ctd\u003eNUXIPIM\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eGeneric Name\u003c\/td\u003e\r\\n\u003ctd\u003eCefepime\u003c\/td\u003e\r\\n\u003ctd\u003eCefepime\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eActive Ingredient\u003c\/td\u003e\r\\n\u003ctd\u003eCefepime 500mg\u003c\/td\u003e\r\\n\u003ctd\u003eCefepime 1000mg\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eDosage Form\u003c\/td\u003e\r\\n\u003ctd\u003ePowder for Injection\u003c\/td\u003e\r\\n\u003ctd\u003ePowder for Injection\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eDrug Class\u003c\/td\u003e\r\\n\u003ctd\u003eAntibiotic\u003c\/td\u003e\r\\n\u003ctd\u003eAntibiotic\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003ePharmacological Class\u003c\/td\u003e\r\\n\u003ctd\u003e4th-Generation Cephalosporin\u003c\/td\u003e\r\\n\u003ctd\u003e4th-Generation Cephalosporin\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eRoute\u003c\/td\u003e\r\\n\u003ctd\u003eIV \/ IM\u003c\/td\u003e\r\\n\u003ctd\u003eIV \/ IM\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eSolvent Presentation\u003c\/td\u003e\r\\n\u003ctd\u003e5mL Sterile Water for Injection\u003c\/td\u003e\r\\n\u003ctd\u003e10mL Sterile Water for Injection\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003ePack Size\u003c\/td\u003e\r\\n\u003ctd\u003e1 Vial + 1 Ampoule\u003c\/td\u003e\r\\n\u003ctd\u003e1 Vial + 1 Ampoule\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eManufacturer\u003c\/td\u003e\r\\n\u003ctd\u003eBosch Pharmaceuticals (Pvt.) Ltd.\u003c\/td\u003e\r\\n\u003ctd\u003eBosch Pharmaceuticals (Pvt.) Ltd.\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eCountry of Manufacture\u003c\/td\u003e\r\\n\u003ctd\u003ePakistan\u003c\/td\u003e\r\\n\u003ctd\u003ePakistan\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003ePrescription Status\u003c\/td\u003e\r\\n\u003ctd\u003ePrescription Medicine\u003c\/td\u003e\r\\n\u003ctd\u003ePrescription Medicine\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003c\/tbody\u003e\r\\n\u003c\/table\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":44164578312251,"sku":null,"price":0.0,"currency_code":"PKR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0695\/4899\/8715\/files\/LUXIPEN-500MG-INJ.jpg?v=1789028818","url":"https:\/\/pharmaservicesgroup.com\/products\/nuxipim-500mg-1g-injection-cefepime-pharma-services-group","provider":"Pharma Services Distribution","version":"1.0","type":"link"}